(Q47569669)

4 February 2018

title

Pharmacodynamic comparison of LY3023703, a novel microsomal prostaglandin e synthase 1 inhibitor, with celecoxib (English)

1 reference

4 February 2018

1 reference

1 reference

Y Jin

1

1 reference

4 February 2018

C L Smith

2

1 reference

4 February 2018

L Hu

3

1 reference

4 February 2018

K M Campanale

4

1 reference

4 February 2018

R Stoltz

5

1 reference

4 February 2018

L G Huffman

6

1 reference

4 February 2018

T A McNearney

7

1 reference

4 February 2018

X Y Yang

8

1 reference

4 February 2018

B L Ackermann

9

1 reference

4 February 2018

R Dean

10

1 reference

4 February 2018

A Regev

11

1 reference

4 February 2018

W Landschulz

12

1 reference

4 February 2018

language of work or name

English

0 references

publication date

9 September 2015

1 reference

4 February 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

4 February 2018

volume

99

1 reference

4 February 2018

issue

3

1 reference

4 February 2018

page(s)

274-284

1 reference

4 February 2018

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

cites work

1 reference

Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure

21 January 2018

1 reference

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

21 January 2018

1 reference

Targeted deletions of cyclooxygenase-2 and atherogenesis in mice.

21 January 2018

1 reference

Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin e synthase-1.

21 January 2018

1 reference

Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation.

21 January 2018

1 reference

Prostacyclin in vascular diseases. - Recent insights and future perspectives -.

21 January 2018

1 reference

Vascular COX-2 modulates blood pressure and thrombosis in mice.

21 January 2018

1 reference

Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis.

21 January 2018

1 reference

Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers

21 January 2018

1 reference

Paired analysis of urinary thromboxane B2 metabolites in humans.

21 January 2018

1 reference

Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis

21 January 2018

1 reference

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus

21 January 2018

1 reference

Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors

21 January 2018

1 reference

Analysis of pharmacokinetic data using parametric models. III. Hypothesis tests and confidence intervals

21 January 2018

1 reference

The structure of the major urinary metabolite of prostaglandin E2 in man

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CPT.260

1 reference

4 February 2018

1 reference

4 February 2018